In vivo imaging of adenovirus transduction and enhanced therapeutic efficacy of combination therapy with conditionally replicating adenovirus and adenovirus-p27

Cancer Research

Volumn 66, Issue 1, 2006, Pages 372-377

  Lee, Choon Taek ^a,c   Lee, Yoon Jin ^a,c   Kwon, Sung Youn ^a,c   Lee, Jaeho ^a,c   Kim, Kwang Il ^b   Park, Kyung Ho ^d   Kang, Joo Hyun ^b   Yoo, Chul Gyu ^a   Kim, Young Whan ^a   Han, Sung Koo ^a   Chung, June Key ^b   Shim, Young Soo ^a   Curiel, David T ^e   Carbone, David P ^d  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

^e UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS PROTEIN P27; LUCIFERASE; PROTEIN P27; UNCLASSIFIED DRUG;

ADENOVIRUS; ARTICLE; BIOLUMINESCENCE; CANCER CELL CULTURE; DRUG EFFICACY; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMAGING SYSTEM; PRIORITY JOURNAL; TUMOR XENOGRAFT; VIRUS EXPRESSION; VIRUS INFECTION; VIRUS MUTANT; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; GENE EXPRESSION; GENE THERAPY; HUMANS; LUCIFERASES; LUMINESCENT MEASUREMENTS; LUNG NEOPLASMS; MICE; TRANSDUCTION, GENETIC; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 31544443219     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-1515     Document Type: Article

References (36)

1. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kim DH. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997;3: 639-45.
2. Heise C, Hermiston T, Johnson L, et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 2000;6:1134-9.
3. Kim D. Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer. Oncogene 2000;19;6660-9.
4. Nemunaitis J, Khuri F, Ganly I, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 2001; 19:289-98.
5. Kim D. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther 2001; 8:89-98.
6. Reid T, Warren R, Kim D. Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther 2002;9:979-86.
7. Bischoff JR, Kim DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996;274:373-6.
8. Lee CT, Park KH, Yanagisawa K, et al. Combination therapy with conditionally replicating adenovirus and replication defective adenovirus. Cancer Res 2004;64: 6660-5.
9. Dion LD, Goldsmith KT, Garver RI, Jr. Quantitative and in vivo activity of adenoviral-producing cells made by cotransduction of a replication-defective adenovirus and a replication-enabling plasmid. Cancer Gene Ther 1996;3:230-7.
10. Goldsmith KT, Dion LD, Curiel DT, Garver RI, Jr. trans E1 component requirements for maximal replication of E1-defective recombinant adenovirus. Virology 1998;248:406-19.
11. Alemany R, Lai S, Lou YC, Jan HY, Fang X, Zhang WW. Complementary adenoviral vectors for oncolysis. Cancer Gene Ther 1999;6:21-5.
12. Wolkersdorfer GW, Morris JC, Ehninger G, Ramsey WJ. Trans-complementing adenoviral vectors for oncolytic therapy of malignant melanoma. J Gene Med 2004; 6:652-62.
13. Habib NA, Mitry R, Seth P, et al. Adenovirus replication-competent vectors (KD1, KD3) complement the cytotoxicity and transgene expression from replication-defective vectors (Ad-GFP, Ad-Luc). Cancer Gene Ther 2002;9:651-4.
14. Lee CT, Park KH, Adachi Y, et al. Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate antitumor effects on lung cancer. Cancer Gene Ther 2003;10:57-63.
15. Choy G, Choyke P, Libutti SK. Current advances in molecular imaging: noninvasive in vivo bioluminescent and fluorescent optical imaging in cancer research. Mol Imaging 2003;2:303-12.
16. Witlox AM, Van Beusechem VW, Molenaar B, et al. Conditionally replicative adenovirus with tropism expanded towards integrins inhibits osteosarcoma tumor growth in vitro and in vivo. Clin Cancer Res 2004;10:61-7.
17. Park KH, Seol JY, Kim TY, et al. An adenovirus expressing mutant p27 showed more potent antitumor effects than adenovirus-p27 wild type. Cancer Res 2001; 61:6163-9.
18. Wildner O, Blaese RM, Morris JC. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res 1999;59:410-3.
19. Nanda D, Vogels R, Havenga M, Avezaat CJ, Bout A, Smitt PS. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase. Cancer Res 2001;61: 8743-50.
20. Seo E, Abei M, Wakayama M, et al. Effective gene therapy of biliary tract cancers by a conditionally replicative adenovirus expressing uracil phosphoribosyltransferase: significance of timing of 5-fluorouracil administration. Cancer Res 2005;65:546-52.
21. Geoerger B, Vassal G, Opolon P, et al. Oncolytic activity of p53-expressing conditionally replicative adenovirus AdΔ24-p53 against human malignant glioma. Cancer Res 2004;64:5753-9.
22. Huang Q, Zhang X, Wang H, et al. A novel conditionally replicative adenovirus vector targeting telomerase-positive tumor cells. Clin Cancer Res 2004; 10:1439-45.
23. Huang TG, Savontaus MJ, Shinozaki K, Sauter BV, Woo SL. Telomerase-dependent oncolytic adenovirus for cancer treatment Gene Ther 2003;10:1241-7.
24. Kanerva A, Bauerschmitz GJ, Yamamoto M, et al. A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma. Gene Ther 2004;11: 552-9.
25. Davydova J, Le LP, Gavrikova T, Wang M, Krasnykh V, Yamamoto M. Infectivity-enhanced cyclooxygenase-2-based conditionally replicative adenoviruses for esophageal adenocarcinoma treatment. Cancer Res 2004;64: 4319-27.
26. Contag CH, Spilman SD, Contag PR, et al. Visualizing gene expression in living mammals using a bioluminescent reporter. Photochem Photobiol 1997;66:523-31.
27. Rehemtulla A, Hall DE, Stegman LD, et al. Molecular imaging of gene expression and efficacy following adenoviral-mediated brain tumor gene therapy. Mol Imaging 2002;1:43-55.
28. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501-12.
29. Coats S, Flanagan WM, Nourse J, Roberts JM. Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle. Science 1996;272:877-80.
30. Sheaff RJ, Groudine M, Gordon M, Roberts JM, Clurman BE. Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev 1997;11:1464-78.
31. Park KH, Seol JY, Yoo CG, et al. Adenovirus expressing p27(Kip1) induces growth arrest of lung cancer cell lines and suppresses the growth of established lung cancer xenografts. Lung Cancer 2001; 31:149-55.
32. Pagano M, Tam SW, Theodoras AM, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995;269:682-5.
33. Vlach J, Hennecke S, Amati B. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J 1997;16:5334-44.
34. Sasaki T, Katayose Y, Suzuki M, et al. Adenovirus expressing mutant p27kip1 enhanced apoptosis against cholangiocarcinoma than adenovirus-p27kip1 wild type. Hepatogastroenterology 2004;51:68-75.
35. Park KH, Lee J, Yoo CG, et al. Application of p27 gene therapy for human malignant glioma potentiated by using mutant p27. J Neurosurg 2004;101: 505-10.
36. Suzuki K, Alemany R, Yamamoto M, Curiel DT. The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses. Clin Cancer Res 2002;8:3348-59.